For patients with CV disease and type 2 diabetes,*
Jardiance® allows you to do more to protect your patients
from the risk of CV death†,1,2,6
Early and sustained reduction in CV death2-4
CV: Cardiovascular. RRR: Relative risk reduction. HR: Hazard ratio. CI: Confidence interval. MI: Myocardial infarction.
CAD: Coronary artery disease. PAD: Peripheral artery disease.
Primary outcome was reduction in CV events defined as composite endpoint of CV death, non-fatal MI, or non-fatal stroke.
Jardiance® reduced the relative risk of CV events by 14% (HR=0.86; 95.02% CI: 0.74, 0.99; p=0.04). CV death was significantly reduced by
38% with no significant difference in non-fatal MI or non-fatal stroke.1,2
* Adult patients with insufficiently controlled type 2 diabetes and CAD, PAD, or a history of MI or stroke.1,2
† The 38% RRR in CV death was achieved in the overall EMPA-REG OUTCOME® population for the duration of the trial.1,3
‡ Pooled data from 10 mg and 25 mg doses of Jardiance®; both doses showed a comparable reduction in the risk of CV death.1,2
§ A post-hoc analysis of data from the EMPA-REG OUTCOME® Trial by baseline HbA1c subgroups. EMPA-REG OUTCOME®
was not powered to show differences between sub-groups.2,4
|| Hazard ratios are related to CV death: HbA1c
HR=0.67 (95% CI: 0.45, 0.99); HbA1c ≥9% HR=0.76 (95% CI: 0.44, 1.31); p=0.41 for interaction.4
1. Jardiance® approved prescribing information, Boehringer lngelheim India, Version 28th Feb, 2020.
2. Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med.
3. Fitchett D, Inzucchi SE, Lachin JM, et al. Cardiovascular mortality reduction with empagliflozin in patients with type 2 diabetes and cardiovascular
disease. J Am Coll Cardiol. 2018;71(3):364-367.
4. Inzucchi SE, Kosiborod M, Fitchett D, et al. Improvement in cardiovascular outcomes with empagliflozin is independent of glycemic control.
5. Claggett B, Lachin JM, Hantel S, et al. Long-term benefit of empagliflozin on life expectancy in patients with type 2 diabetes mellitus and
established cardiovascular disease: Survival estimates from the EMPA-REG OUTCOME® Trial. Circulation. 2018;138:1599-1601.
6. Piepoli MF, Hoes AW, Agewall S, et al. European Guidelines on cardiovascular disease prevention in clinicalpractice: The Sixth Joint Task Force of the
European Society of Cardiology and other Societies on Cardiovascular Disease Prevention in Clinical Practice. Eur Heart J. 2016;37(29):2315-2381.